Biomarker method validation in anticancer drug development

被引:91
作者
Cummings, J. [1 ]
Ward, T. H. [1 ]
Greystoke, A. [1 ]
Ranson, M. [2 ]
Dive, C. [1 ]
机构
[1] Univ Manchester, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
关键词
biomarker; method validation; clinical trials; anticancer drugs; mass spectrometry; M30 and M65 ELISAs;
D O I
10.1038/sj.bjp.0707441
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over recent years the role of biomarkers in anticancer drug development has expanded across a spectrum of applications ranging from research tool during early discovery to surrogate endpoint in the clinic. However, in Europe when biomarker measurements are performed on samples collected from subjects entered into clinical trials of new investigational agents, laboratories conducting these analyses become subject to the Clinical Trials Regulations. While these regulations are not specific in their requirements of research laboratories, quality assurance and in particular assay validation are essential. This review, therefore, focuses on a discussion of current thinking in biomarker assay validation. Five categories define the majority of biomarker assays from 'absolute quantitation' to 'categorical'. Validation must therefore take account of both the position of the biomarker in the spectrum towards clinical end point and the level of quantitation inherent in the methodology. Biomarker assay validation should be performed ideally in stages on 'a fit for purpose' basis avoiding unnecessarily dogmatic adherence to rigid guidelines but with careful monitoring of progress at the end of each stage. These principles are illustrated with two specific examples: ( a) absolute quantitation of protein biomarkers by mass spectrometry and (b) the M30 and M65 ELISA assays as surrogate end points of cell death.
引用
收藏
页码:646 / 656
页数:11
相关论文
共 102 条
[21]   Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP [J].
Cummings, J ;
Ward, TH ;
LaCasse, E ;
Lefebvre, C ;
St-Jean, M ;
Durkin, J ;
Ranson, M ;
Dive, C .
BRITISH JOURNAL OF CANCER, 2005, 92 (03) :532-538
[22]  
CUMMINGS J, 2007, CANC CHEMOTHER PHARM
[23]   Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: A prospective pilot study [J].
Demiray, Mutlu ;
Ulukaya, Engin ;
Arslan, Murat ;
Gokgoz, Sehsuvar ;
Saraydaroglu, Ozlem ;
Ercan, Ilker ;
Evrensel, Turkkan ;
Manavoglu, Osman .
CANCER INVESTIGATION, 2006, 24 (07) :669-676
[24]   Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules [J].
DeSilva, B ;
Smith, W ;
Weiner, R ;
Kelley, M ;
Smolec, JM ;
Lee, B ;
Khan, M ;
Tacey, R ;
Hill, H ;
Celniker, A .
PHARMACEUTICAL RESEARCH, 2003, 20 (11) :1885-1900
[25]   Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas [J].
Ditzel, HJ ;
Strik, MCM ;
Larsen, MK ;
Willis, AC ;
Waseem, A ;
Kejling, K ;
Jensenius, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21712-21722
[26]   Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts [J].
Duan, WR ;
Garner, DS ;
Williams, SD ;
Funckes-Shippy, CL ;
Spath, IS ;
Blomme, EAG .
JOURNAL OF PATHOLOGY, 2003, 199 (02) :221-228
[27]   Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry [J].
Engwegen, Judith Y. M. N. ;
Gast, Marie-Christine W. ;
Schellens, Jan H. M. ;
Beijnen, Jos H. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (05) :251-259
[28]  
ENNARSSON R, 1997, J CLIN LIGAND ASSAY, V22, P348
[29]  
*FDA, 1991, COD FED REG TITL 11
[30]  
*FDA, 2001, COD FED REG TITL 42, V3